No Data
BOCOM INTL: Maintains Buy rating for Hutchmed (China) (00013) with the Target Price raised to 44 HKD.
BOCOM INTL believes that the conditions of this Trade involving Hutchmed (China) are reasonable and beneficial for the company's long-term development.
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $26
Hong Kong stock movement | Hutchmed (China) (00013) rises over 4%. The company's sale of non-core Traditional Chinese Medicine Assets will further strengthen its capital and debt structure.
Hutchmed (China) (00013) rose over 4%, as of the time of writing, it increased by 4.3%, trading at HKD 24.25, with a transaction volume of HKD 61.2538 million.
Private Equity Firms Are HUTCHMED (China) Limited's (LON:HCM) Biggest Owners and Were Rewarded After Market Cap Rose by UK£120m Last Week
GF SEC: Maintain the "Buy" rating for Hutchmed (China) (00013) with a fair value of 41.35 HKD.
GF SEC expects Hutchmed (China) to achieve a net income of 0.005, 0.02, and 0.074 billion USD for the years 2024-2026 respectively.
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
